Accreditation Information

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing (ANCC)

This activity is designated for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Upon completion of a CNE request form, statements of credit for nurses will be issued within 30 business days.

ONCC/ILNA Certification Information

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. Certification qualifications will be provided to participants at the live meeting.

ONCC/ILNA Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

Needs Statement

Attendees will gain an appreciation of the latest clinical and scientific advances in targeting DNA damage response (DDR) for the treatment of ovarian, breast, prostate, and pancreatic cancers, including updates on the current and emerging prospects of poly-ADP ribose polymerase (PARP) inhibitors. They will also gain an appreciation of the importance of recommended genetic testing and counseling in patients with possible pathogenic DDR mutations and their implications on patient management strategies. Potential strategies for the oncology nurse to optimize therapy, anticipate adverse events, and improve adherence will also be discussed in this case-based presentation.

Objectives

  1. Outline key mechanisms in the DNA damage response pathway and their role in tumor suppression.
  2. Appraise the importance of recommended genetic testing and counseling in patients with possible pathogenic DNA damage response mutations and their implications on patient management strategies.
  3. Assess the current and emerging data on safety and efficacy of DNA damage response targeting therapies, such as PARP inhibitors, in patients with ovarian, breast, prostate, or pancreatic cancer.
  4. Using a case-based approach, evaluate challenging questions regarding the use of PARP inhibitors and discuss ways the oncology nurse can optimize therapy, anticipate adverse effects, and play a role in improving adherence strategies. 

Target Audience

This activity is designed to meet the educational needs of oncology nurses and nurse practitioners attending local ONS Chapter Meetings across the U.S.

Faculty Disclosure

Planner and Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner: 
Vanessa Carranza, PharmD - has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters:
Paula J. Anastasia, RN, MN, AOCN - has disclosed that she is a member of the speakers’ bureaus for Clovis and Genentech.

Lisa Arvine, RN, MSN, ANP-BC, WHNP-BC - has no relevant financial relationships to disclose in relation to the content of this activity.

Chrisann A. Winslow, RN, BSN, MSN(R), AOCN - has disclosed that she is a member of the speakers’ bureau for Clovis.

Lisa M. Doyle, MSN, FNP-BC, OCN - has no relevant financial relationships to disclose in relation to the content of this activity.

Gabriela Lacatus, RN, BSN, OCN, PhD - has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewer:

Lisa M. Doyle, MSN, FNP-BC, OCN - has no relevant financial relationships to disclose in relation to the content of this activity.